A new white paper from the Network for Excellence in Health Innovation encourages the use of outcomes-based contracting for novel oncology drugs.
Smita Jaggernauth, PharmD
Advertisement
Articles by Smita Jaggernauth, PharmD
A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non–small lung cancer (NSCLC).
Advertisement
Latest Updated Articles
Mutation May Be Associated With Resistance to NSCLC ImmunotherapyPublished: November 8th 2017 | Updated:
NEHI Recommends Implementing Value-Based Contracts With High-Cost Oncology TreatmentsPublished: November 12th 2017 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
4
Value-Based Care Interventions and Management of CKD Progression
5
